Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$1.03M+303.14%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Laura E. Niklason
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 184
- Beta
- 2.68
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -9.86
Financials
Revenue
$1.03M+303.1%Net Income
$-15.54MEBITDA
$-12.04MFree Cash Flow
$-14.97MEPS (diluted)
$-0.06Shares Outstanding (diluted)
277.80M+169.7%Operating Expenses
$23.12MCash & Debt
$64.52MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.04M | $-40.83M | $-0.26 |
| 2024 | $0.00 | $-148.70M | $-1.26 |
| 2023 | $0.00 | $-110.78M | $-1.07 |
| 2022 | $1.56M | $-11.96M | $-0.12 |
| 2021 | $1.26M | $-26.48M | $-0.66 |
| 2020 | $1.49M | $-66.52M | $-5.52 |
| 2019 | $6.19M | $-85.42M | $-4.25 |
Valuation
HUMAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30+50.00%Social Signal Score
Mentions (28)
- Newsglobenewswire.com·3d ago·Negative
Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access –sBLA submission seeks to add arteriovenous access for hemodialysis as second approved indication for the ATEV. –sBLA supported by results from three Phase 3 studies in hemodialysis access.
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel – Analysis of ATEVs from 52 patients across five clinical trials, some implanted for more than five years, found minimal lipid buildup and no evidence of vulnerable plaques. – First long-term clinical evaluation of atherosclerosis susceptibility in a tissue engineered vessel.
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
Five Presentations, One Leading Innovation: Humacyte's Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026 – Presentations include interim Phase 3 results in women, integrated outcomes from three Phase 3 dialysis access trials and long-term human explant data. – Podium presentation to provide an update on clinical results with Symvess® in military and civilian trauma settings.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Humacyte, Inc. (HUMA) Q3 2026 Earnings Call Transcript Humacyte, Inc. (HUMA) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
Humacyte Q3 Earnings Call Highlights Humacyte NASDAQ: HUMA reported third-quarter Symvess sales of approximately $1 million, up 151% from the preceding quarter, and said it expects sales to at least double again in the fourth quarter as more hospitals adopt the product.
View source ↗ - Newszacks.com·12d ago·Negative
Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.14 per share a year ago.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption – Commercial adoption of Symvess® accelerated during the third quarter with sales totaling $1.0 million, a 151% increase over the 2 nd quarter. – Symvess commercial momentum continued into the fourth quarter, with October 2026 sales totaling $0.8 million.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026 – Humacyte has initiated the CABG clinical study and looks forward to the commencement of screening for potential patients. – “Moving it into a first-in-human study is the step that will tell us whether an off-the-shelf conduit can perform in the coronary position,” says cardiothoracic surgeon Alan Kypson, M.D.
View source ↗ - Newszacks.com·17d ago·Neutral
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.4, representing a -12.11% change from its previous close.
View source ↗ - Newszacks.com·23d ago·Neutral
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights Humacyte, Inc. (HUMA) concluded the recent trading session at $0.41, signifying a -13.01% move from its prior day's close.
View source ↗ - Newsglobenewswire.com·25d ago·Negative
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues – Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C.
View source ↗ - Newsglobenewswire.com·30d ago·Positive
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner - The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaningful new option.”
View source ↗ - Newszacks.com·32d ago·Neutral
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today Humacyte, Inc. (HUMA) closed at $0.41 in the latest trading session, marking a +1.28% move from the prior day.
View source ↗ - Newszacks.com·34d ago·Positive
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.
View source ↗ - Newszacks.com·40d ago·Neutral
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know Humacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.
View source ↗ - Newszacks.com·47d ago·Neutral
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.
View source ↗ - Newszacks.com·52d ago·Positive
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company's Board of Directors, both of whom bring substantial experience in the areas of commercializatio…
View source ↗ - Newszacks.com·58d ago·Positive
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.
View source ↗ - Newszacks.com·65d ago·Neutral
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
View source ↗ - Newszacks.com·66d ago·Neutral
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
View source ↗ - Newsglobenewswire.com·74d ago·Negative
…inues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has authorized an extension of the expiration dating period for Symvess® (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated a…
View source ↗ - Newsglobenewswire.com·90d ago·Negative
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions – Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
View source ↗ - Newsglobenewswire.com·95d ago·Neutral
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results – Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –
View source ↗ - Newsglobenewswire.com·96d ago·Negative
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement” – Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
Humacyte Q2 Earnings Call Highlights Humacyte NASDAQ: HUMA reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update – Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 –
View source ↗
Earnings
Fri, Mar 26(in 4 months)
Consensus estimate $-0.07 per share
Typical surprise +10.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.07 vs $-0.10beat
- Wed, Aug 12$-0.16 vs $-0.11miss
- Wed, May 13$-0.09 vs $-0.10beat
- Fri, Mar 27$-0.13 vs $-0.13beat
- Wed, Nov 12$-0.14 vs $-0.17beat
- Mon, Aug 11$-0.24 vs $-0.15miss
Estimates and results for HUMA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HUMA officers and directors.
- Bought
- $308k
- Sold
- $37.2m
17 trades
27 trades
- Jones Keith Anthonybought
- Jones Keith Anthonybought
- Jones Keith Anthonybought
- Sebelius Kathleenbought
- Constantino Michael T.bought
- Sander Dale A.sold
- Parikh Shamik Jsold
- Dougan Brady Wsold
56 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (867d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (867d later)Buy$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (867d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (867d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jun 14, 2024 (42d later)Sell$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jun 14, 2024 (42d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed May 15, 2024 (15d later)Sell$50,001 - $100,000
- Thomas Hawley Tubervillesenate · AL · disclosed Apr 15, 2024 (25d later)Buy$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed Mar 15, 2024 (32d later)Buy$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed Feb 14, 2024 (26d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 14, 2023 (20d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Apr 8, 2022 (9d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
